Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > Articles online first > The Journal of Cardiovascular Surgery 2017 Mar 28

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

The Journal of Cardiovascular Surgery 2017 Mar 28

DOI: 10.23736/S0021-9509.17.09963-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

The role of drug-coated balloons in in-stent restenosis

Martin ANDRASSY 1 , Sultan CELIK 1, Joachim ANDRASSY 2, Michael K. LICHTENBERG 3, Marianne BRODMANN 4

1 Cardiology/Angiology, Medical Department II, Fürst-Stirum Clinic, Bruchsal, Germany; 2 Department of Surgery, University Hospital Munich, Munich, Germany; 3 Vascular Center, Arnsberg Clinic, Arnsberg, Germany; 4 Department of Angiology, University of Graz, Graz, Austria


PDF  


INTRODUCTION: Despite a constantly expanding spectrum of therapeutic options for lower limb artery disease, there is not yet a well-defined consensus on the specific type of endovascular treatment that is best suited. Clinical data on patients with femoropopliteal disease treated with drug-coated balloons have not been elaborated sufficiently, especially in the case of in-stent restenosis (ISR).
EVIDENCE ACQUISITION: For this review a systematic research of the medical databases (http://www.ncbi.nlm.nih.gov/pubmed/) has been conducted.
EVIDENCE SYNTHESIS: Keywords such as drug-coated balloons (DCB)/drug-eluting balloons (DEB), in-stent restenosis, de novo stenosis, angioplasty, superficial femoral artery(SFA), popliteal artery (PA), above the knee (ATK), below the knee (BTK), peripheral artery disease (PAD) have been used. Furthermore, data from reviews, original contributions regarding randomized controlled studies, observational studies, registries and single center experiences have been included.
CONCLUSIONS: Many trials have shown superiority for DCB- over PTA-treatment alone in TASC IIA and TASC IIB femoropopliteal lesions. However, the currently available DCB systems are different in terms of efficacy and long-term outcomes depending on their mechanical and pharmacological features. Moreover, angiographic characteristics of femoropopliteal lesions classified by Tosaka seem to influence subsequent outcomes of DCB treatment. Lastly, there is still lack of reliable prospective long-term data regarding DCB technology.


KEY WORDS: Drug-coated balloon - In-stent restenosis - Stent technologies

top of page

Publication History

Cite this article as

Corresponding author e-mail

martin.andrassy@kliniken-lk.de